Stock Analysis on Net
Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

Common-Size Income Statement 
Quarterly Data

Eli Lilly & Co., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -18.98 -19.20 -19.09 -19.12 -19.58 -21.74 -23.37 -21.20 -22.75 -22.05 -26.53 -25.63 -21.13 -28.98 -27.60 -23.12 -23.11 -22.22 -20.74 -20.98 -21.45 -19.96 -22.36
Gross margin 81.02% 80.80% 80.91% 80.88% 80.42% 78.26% 76.63% 78.80% 77.25% 77.95% 73.47% 74.37% 78.87% 71.02% 72.40% 76.88% 76.89% 77.78% 79.26% 79.02% 78.55% 80.04% 77.64%
Research and development -23.90 -23.99 -28.77 -27.40 -25.36 -28.35 -28.52 -27.33 -25.97 -27.46 -20.62 -23.73 -25.18 -24.55 -24.57 -24.70 -25.53 -25.28 -23.76 -25.87 -25.21 -24.88 -24.16
Marketing, selling, and administrative -18.36 -18.73 -22.27 -20.58 -18.99 -23.16 -25.13 -22.50 -23.25 -25.05 -19.95 -19.90 -23.30 -25.01 -23.16 -20.89 -27.33 -26.34 -26.44 -27.77 -25.79 -28.14 -29.79
Acquired in-process research and development -24.71 -1.37 -1.26 -6.66 -31.32 -1.17 -1.51 -3.29 -0.90 -6.79 -2.12 -5.47 -2.62 -0.64 -4.58 -4.92 0.00 -4.40 -0.89 0.00 -1.42 -0.44 -2.69
Asset impairment, restructuring, and other special charges -0.71 -3.85 0.00 -0.72 0.00 0.00 0.00 -0.52 -2.97 0.00 0.00 -1.31 0.00 0.00 -3.11 0.40 -1.77 0.00 -1.02 -2.48 0.00 0.00 -8.32
Operating income 13.34% 32.87% 28.62% 25.53% 4.74% 25.57% 21.47% 25.15% 24.15% 18.65% 30.78% 23.97% 27.78% 20.82% 16.98% 26.78% 22.27% 21.76% 27.15% 22.90% 26.12% 26.58% 12.67%
Other, net, income (expense) 0.54 -1.75 0.31 1.29 -0.24 -0.44 0.51 3.56 -1.60 -1.84 -4.49 -0.97 -9.39 2.83 4.72 6.41 2.77 8.13 1.52 4.30 -0.45 -0.57 1.69
Income before income taxes 13.89% 31.12% 28.92% 26.82% 4.50% 25.13% 21.98% 28.71% 22.55% 16.81% 26.29% 23.00% 18.39% 23.65% 21.69% 33.19% 25.04% 29.89% 28.67% 27.20% 25.67% 26.01% 14.36%
Income taxes -5.40 -4.87 -3.34 -3.41 -5.10 -3.92 -2.66 -2.17 -1.64 -2.13 -1.93 -1.42 -2.00 -3.02 -1.78 -4.74 -3.99 -4.21 -3.81 -2.74 -2.77 -2.46 -3.34
Net income (loss) from continuing operations 8.48% 26.25% 25.58% 23.41% -0.60% 21.21% 19.32% 26.54% 20.91% 14.68% 24.36% 21.58% 16.39% 20.63% 19.91% 28.45% 21.05% 25.68% 24.86% 24.46% 22.90% 23.55% 11.02%
Net income from discontinued operations 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 72.28
Net income (loss) 8.48% 26.25% 25.58% 23.41% -0.60% 21.21% 19.32% 26.54% 20.91% 14.68% 24.36% 21.58% 16.39% 20.63% 19.91% 28.45% 21.05% 25.68% 24.86% 24.46% 22.90% 23.55% 83.30%

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Eli Lilly & Co. operating income as a percentage of revenue increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Eli Lilly & Co. income before income taxes as a percentage of revenue increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Eli Lilly & Co. net income (loss) as a percentage of revenue increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.